Cocktail Drugs

Font Size

Print

Feedback

Email

Discuss

Related Articles

Pfizer’s Handa is new MD of Wyeth IndiaLower forex losses put Ranbaxy back in the blackPfizer profit up 26% on job cutsPfizer forms policies to raise standards

: and the UK.

Local clinical trials for DRL’s polypill were completed in July last year across 11 centres in the country. “The evidence from the clinical data is very strong. It is not an irrational combination and we have got solid clinical evidence with our data,”

says Cidambi.

“Our offering is unique as it does not fall under any blockbuster category nor traditional drugs; but a new molecule, which would be made available to the needy at an affordable price,” he insists.

The cost of a monthly course (30 tablets) of DRL’s polypill will work out to only Rs100, compared to the prevailing cost of Rs 400-500 for multiple tablets, travails included. Isn’t it surprising? But, this is the promise these wonder drugs hold for patients and doctors alike.

The significance of this breakthrough is multi-pronged. Firstly, the medical fraternity is finally working on prevention of diseases plaguing mankind, instead of the earlier practice of focusing on its treatment. Secondly, the polypill approach is being directed not only towards those at the risk of heart problems and stroke, but also towards the treatment and prevention of equally devastating illnesses like tuberculosis (TB), malaria and HIV. It is believed that several domestic drug companies have intensified their research efforts in their endeavour to develop combination drugs. Those closer to the market include one that brings together two asthma medications and another that combines three HIV drugs. Thirdly, the polypill approach is opening another vista to the Indian drug companies to tap the global markets. Their research efforts are getting strengthened in their ability to develop affordable combination drugs that focus on the treatment of various diseases as well as their prevention.

Current treatment usually involves treating one cardiovascular problem with at least two drugs. Future treatment would involve treating a group of cardiovascular problems with one pill containing multiple drugs.

“Since Indians are at a high risk of contracting cardiovascular diseases, development of such a polypill, which combines multiple drugs proven to be of benefit for heart diseases, makes sense,” says Anoop Misra, director and head, department of diabetes and metabolic diseases, Fortis Hospitals (New Delhi and Noida).

Every year, over 17.5 million people die due to heart diseases all over the world. India has the dubious distinction of having the largest share—over 2.8 million.